Cabergoline reduces the early onset of ovarian hyperstimulation syndrome

A prospective randomized study

Carlos Carizza, Vicente Abdelmassih, Soraya Abdelmassih, Pedro Ravizzini, Lister Salgueiro, Paulo Tudech Salgueiro, Lin Tao Jine, P. Nagy, Roger Abdelmassih

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Prophylactic use of cabergoline has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). A prospective randomized study was designed to evaluate the potential of cabergoline to decrease the incidence of OHSS in high-risk patients undergoing assisted reproductive technology treatment; 166 patients with oestradiol concentrations over 4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration were evaluated. They all received 20 g routine preventive intravenous human albumin on the day of oocyte retrieval. They were then randomized into two groups: group A (n = 83) received 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval, and group B (n = 83) received no medication. 'Early' OHSS was defined as being when the onset of the syndrome was initiated during the first 9 days after HCG administration, and 'late' OHSS was defined as being when the onset of the syndrome was initiated from 10 days after HCG administration. In group A, no patients progressed to 'early' OHSS and nine patients (10.8%) developed 'late' OHSS; in group B, 12 patients (15.0%) progressed to 'early' OHSS and three (3.8%) to 'late' OHSS. Although the risk of 'early' OHSS decreased significantly (P <0.001), the risk of 'late' onset OHSS did not. The two groups presented no changes in pregnancy, implantation or miscarriages rate.

Original languageEnglish
Pages (from-to)751-755
Number of pages5
JournalReproductive BioMedicine Online
Volume17
Issue number6
Publication statusPublished - Dec 2008

Fingerprint

Ovarian Hyperstimulation Syndrome
Prospective Studies
Chorionic Gonadotropin
Oocyte Retrieval
cabergoline
Assisted Reproductive Techniques
Spontaneous Abortion
Albumins
Estradiol

Keywords

  • Cabergoline
  • Early
  • Late
  • OHSS
  • Onset
  • Prevention

ASJC Scopus subject areas

  • Reproductive Medicine
  • Developmental Biology

Cite this

Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P. T., ... Abdelmassih, R. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reproductive BioMedicine Online, 17(6), 751-755.

Cabergoline reduces the early onset of ovarian hyperstimulation syndrome : A prospective randomized study. / Carizza, Carlos; Abdelmassih, Vicente; Abdelmassih, Soraya; Ravizzini, Pedro; Salgueiro, Lister; Salgueiro, Paulo Tudech; Jine, Lin Tao; Nagy, P.; Abdelmassih, Roger.

In: Reproductive BioMedicine Online, Vol. 17, No. 6, 12.2008, p. 751-755.

Research output: Contribution to journalArticle

Carizza, C, Abdelmassih, V, Abdelmassih, S, Ravizzini, P, Salgueiro, L, Salgueiro, PT, Jine, LT, Nagy, P & Abdelmassih, R 2008, 'Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study', Reproductive BioMedicine Online, vol. 17, no. 6, pp. 751-755.
Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reproductive BioMedicine Online. 2008 Dec;17(6):751-755.
Carizza, Carlos ; Abdelmassih, Vicente ; Abdelmassih, Soraya ; Ravizzini, Pedro ; Salgueiro, Lister ; Salgueiro, Paulo Tudech ; Jine, Lin Tao ; Nagy, P. ; Abdelmassih, Roger. / Cabergoline reduces the early onset of ovarian hyperstimulation syndrome : A prospective randomized study. In: Reproductive BioMedicine Online. 2008 ; Vol. 17, No. 6. pp. 751-755.
@article{0e4f0bb1f5904098a770c48d7bbb9db5,
title = "Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study",
abstract = "Prophylactic use of cabergoline has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). A prospective randomized study was designed to evaluate the potential of cabergoline to decrease the incidence of OHSS in high-risk patients undergoing assisted reproductive technology treatment; 166 patients with oestradiol concentrations over 4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration were evaluated. They all received 20 g routine preventive intravenous human albumin on the day of oocyte retrieval. They were then randomized into two groups: group A (n = 83) received 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval, and group B (n = 83) received no medication. 'Early' OHSS was defined as being when the onset of the syndrome was initiated during the first 9 days after HCG administration, and 'late' OHSS was defined as being when the onset of the syndrome was initiated from 10 days after HCG administration. In group A, no patients progressed to 'early' OHSS and nine patients (10.8{\%}) developed 'late' OHSS; in group B, 12 patients (15.0{\%}) progressed to 'early' OHSS and three (3.8{\%}) to 'late' OHSS. Although the risk of 'early' OHSS decreased significantly (P <0.001), the risk of 'late' onset OHSS did not. The two groups presented no changes in pregnancy, implantation or miscarriages rate.",
keywords = "Cabergoline, Early, Late, OHSS, Onset, Prevention",
author = "Carlos Carizza and Vicente Abdelmassih and Soraya Abdelmassih and Pedro Ravizzini and Lister Salgueiro and Salgueiro, {Paulo Tudech} and Jine, {Lin Tao} and P. Nagy and Roger Abdelmassih",
year = "2008",
month = "12",
language = "English",
volume = "17",
pages = "751--755",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Cabergoline reduces the early onset of ovarian hyperstimulation syndrome

T2 - A prospective randomized study

AU - Carizza, Carlos

AU - Abdelmassih, Vicente

AU - Abdelmassih, Soraya

AU - Ravizzini, Pedro

AU - Salgueiro, Lister

AU - Salgueiro, Paulo Tudech

AU - Jine, Lin Tao

AU - Nagy, P.

AU - Abdelmassih, Roger

PY - 2008/12

Y1 - 2008/12

N2 - Prophylactic use of cabergoline has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). A prospective randomized study was designed to evaluate the potential of cabergoline to decrease the incidence of OHSS in high-risk patients undergoing assisted reproductive technology treatment; 166 patients with oestradiol concentrations over 4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration were evaluated. They all received 20 g routine preventive intravenous human albumin on the day of oocyte retrieval. They were then randomized into two groups: group A (n = 83) received 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval, and group B (n = 83) received no medication. 'Early' OHSS was defined as being when the onset of the syndrome was initiated during the first 9 days after HCG administration, and 'late' OHSS was defined as being when the onset of the syndrome was initiated from 10 days after HCG administration. In group A, no patients progressed to 'early' OHSS and nine patients (10.8%) developed 'late' OHSS; in group B, 12 patients (15.0%) progressed to 'early' OHSS and three (3.8%) to 'late' OHSS. Although the risk of 'early' OHSS decreased significantly (P <0.001), the risk of 'late' onset OHSS did not. The two groups presented no changes in pregnancy, implantation or miscarriages rate.

AB - Prophylactic use of cabergoline has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). A prospective randomized study was designed to evaluate the potential of cabergoline to decrease the incidence of OHSS in high-risk patients undergoing assisted reproductive technology treatment; 166 patients with oestradiol concentrations over 4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration were evaluated. They all received 20 g routine preventive intravenous human albumin on the day of oocyte retrieval. They were then randomized into two groups: group A (n = 83) received 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval, and group B (n = 83) received no medication. 'Early' OHSS was defined as being when the onset of the syndrome was initiated during the first 9 days after HCG administration, and 'late' OHSS was defined as being when the onset of the syndrome was initiated from 10 days after HCG administration. In group A, no patients progressed to 'early' OHSS and nine patients (10.8%) developed 'late' OHSS; in group B, 12 patients (15.0%) progressed to 'early' OHSS and three (3.8%) to 'late' OHSS. Although the risk of 'early' OHSS decreased significantly (P <0.001), the risk of 'late' onset OHSS did not. The two groups presented no changes in pregnancy, implantation or miscarriages rate.

KW - Cabergoline

KW - Early

KW - Late

KW - OHSS

KW - Onset

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=58149103364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149103364&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 751

EP - 755

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 6

ER -